MyFinsight
Home
Blog
About
Contact
Download
Download image
US
$112,600K
Non Us
$14,600K
US
$108,800K
Non Us
$17,800K
US
$49,000K
Non Us
$4,600K
US
$5,000K
Non Us
$300K
Tyvaso DPI
$330,300K
Orenitram
$135,600K
Nebulized Tyvaso
$127,200K
Remodulin
$126,600K
Unituxin
$53,600K
Product And Service
Other
$5,300K
Adcirca
$2,900K
Total revenues
$781,500K
(-1.62%↓ Y/Y)
Operating income
$325,800K
(-14.89%↓ Y/Y)
Total operating
expenses
$455,700K
(10.71%↑ Y/Y)
Income before income
taxes
$318,300K
(-24.84%↓ Y/Y)
Total other (expense)
income, net
-$7,500K
(-118.43%↓ Y/Y)
Interest income
$41,800K
(-18.20%↓ Y/Y)
Selling, general, and
administrative
$184,100K
(8.23%↑ Y/Y)
Research and development
$138,200K
(-7.25%↓ Y/Y)
Cost of sales
$133,400K
(44.22%↑ Y/Y)
Net income
$274,900K
(-14.68%↓ Y/Y)
Income tax expense
$43,400K
(-57.16%↓ Y/Y)
Other expense, net
-$46,300K
(-976.74%↓ Y/Y)
Interest expense
$3,000K
(-50.82%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
UNITED THERAPEUTICS Corp (UTHR)
UNITED THERAPEUTICS Corp (UTHR)